Company
K36tx
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics.
Also known as K36 Therapeutics
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
- k36tx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
K36’s program is the first to study targeting the histone lysine methyltransferase NSD2 (MMSET/WHSC1) for the treatment of hematologic and solid tumor malignancies. By targeting NSD2, K36’s clinical pipeline brings the promise of precision medicine to multiple types of malignancies.
Products
- Other
- Gintemetostat (KTX-1001)
- Other
- KTX-2001
Loading relationship preview